GENETWORx is investing $500 million in diagnostics companies.

Talk to our team about acquisition and funding opportunities before our 2021 investment round closes.

After cementing our position as a national leader in molecular diagnostics through the COVID-19 pandemic, we’ve launched our own equity investment firm, GENETWORx Holdings. We’re committed to augmenting our impact on the pharmacogenomic and diagnostics landscape, pursuing a $500 million investment round to foster innovation in the field.

Join the GENETWORx portfolio today to improve lives and change the world.

Read Our Press Release

Get your company’s valuation now.

Fill out the form below and we’ll be in touch to discuss an offer.

Join GENETWORx in pioneering the future of diagnostic solutions.

GENETWORx Holdings firmly believes the future of healthcare lies in early identification and detection of viral and genetic mutations, as well as the application of those findings to personalized medicines. As a result, we are making considerable investments in the people and technologies capable of rapidly advancing life-changing diagnostics methods and technologies.

As of May 2021, GENETWORx began aggressively acquiring over $500 million dollars in new revenue (regardless of EBITDA), as well as pre-revenue research and development companies which own approved products or technology platforms. Our main area of focus is acquiring and investing in laboratory diagnostics companies which develop and own unique assets in the fields of next-generation sequencing, liquid biopsy, early cancer detection, infectious disease (unrelated to Covid-19), pharmacogenomics, and other laboratory diagnostics.

Why partner with GENETWORx?

Get expert support from a proven name in testing solutions.
The team of scientists and researchers at GENETWORx collaborate with healthcare professionals to provide faster, safer, and more accurate diagnoses and treatments. Throughout the COVID-19 pandemic, GENETWORx has been integral in the diagnosis of COVID-19 for patients nationwide. GENETWORx is also among the leading at-home COVID-19 test kit providers, partnering with communities, local governments, and pharmacies to improve the availability and convenience of testing supplies to Americans.

The global pandemic demonstrated that the science and healthcare communities are capable of developing life-changing and life-saving therapies faster than ever before. Now, GENETWORx Holdings is seeking to bring similar innovations and products to market in the pharmacogenomic field. Joining forces with diagnostics companies like yours can help make this critical goal a reality.

Tap into the collaborative benefits of The Discovery Labs.
Among the first investments made by GENETWORx was the acquisition of the former GlaxoSmithKline R&D facility in King of Prussia, Pennsylvania. The existing property was transformed into a $500 million dollar life science, healthcare, and technology headquarters known as The Discovery Labs. This state-of-the-art facility is integral to the advancement of pharmacogenomic research and technology, fostering groundbreaking collaboration between all business acquisitions and investment partners in the GENETWORx portfolio.

Expand your operational capabilities on your terms.
Whether you’re already earning revenue or preparing an approved IP for launch, GENETWORx Holdings can help finance and market your innovations. Lean on GENETWORx for cash infusions, join them in a 50/50 partnership or bring them on as a minority stakeholder. No matter how you join the portfolio, you’ll gain collaborative input from other leading companies, plus the recognition and reputation associated with the GENETWORx brand.

Secure the legacy of your company long after its sale.
If GENETWORx approaches you with the expressed interest of acquiring your business, you can rest assured that the future of your company is in the most capable hands. Your business very well could be the missing piece for the next world-changing healthcare breakthrough, and GENETWORx Holdings intends to identify and pilot that innovation.

Selling your company isn’t an easy decision after you’ve invested significant time, energy and resources into your success. That’s why GENETWORx develops a relationship with your team, ensuring your best interests are in mind throughout the acquisition process. You’ll get the confidence you need to capitalize on the sale of your business, receive the payday you’ve rightly earned, and spend time enjoying a new chapter of your life.

Ready to explore a relationship with GENETWORx?

Our 2021 fund is currently accepting new investment prospects.

Kevin Rudd

Investment & Acquisitions
610-994-2939
kevinrudd@genetworx.com